FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2529944834> ?p ?o ?g. }

• W2529944834 endingPage "233" @default.
• W2529944834 startingPage "222" @default.
• W2529944834 abstract "BACKGROUND Leucine stimulates cancer cell proliferation through the mTOR pathway, therefore, inhibiting leucine transporters may be a novel therapeutic target for cancer. L‐type amino acid transporter (LAT) 1, a Na + ‐independent amino acid transporter, is highly expressed in many tumor cells. However, leucine transporter(s) in different stages of prostate cancer, particularly in the stages of castration resistance with androgen receptor (AR) expression, is unclear. METHODS LNCaP and DU145 and PC‐3 cell lines were used as a model of androgen dependent, and metastatic prostate cancer. A new “LN‐cr” cell line was established after culturing LNCaP cells for 6 months under androgen‐free conditions, which is considered a model of castration resistant prostate cancer (CRPC) with androgen AR expression. The expression of leucine transporters was investigated with quantitative PCR and immunofluorescence. Uptake of 14 C Leucine was examined in the presence or absence of BCH (a pan‐LAT inhibitor), JPH203 (an LAT1‐specific inhibitor), or Na + . Cell growth was assessed with MTT assay. siRNA studies were performed to evaluate the indispensability of y + LAT2 on leucine uptake and cell viability in LN‐cr. RESULTS Cell viability showed a 90% decrease in the absence of leucine in all four cell lines. LNCaP cells principally expressed LAT3, and their leucine uptake was more than 90% Na + ‐independent. BCH, but not JPH203, inhibited leucine uptake, and cell proliferation (IC 50BCH :15 mM). DU145 and PC‐3 cells predominantly expressed LAT1. Leucine uptake and cell growth were suppressed by BCH or JPH203 in a dose‐dependent manner (IC 50BCH : ∼20 mM, IC 50JPH203 : ∼5 µM). In LN‐cr cells, Na + ‐dependent uptake of leucine was 3.8 pmol/mgprotein/min, while, Na + ‐independent uptake was only 0.52 ( P < 0.05). Leucine uptake of LN‐cr was largely (∼85%) Na + ‐dependent. y + LAT2 expression was confirmed in LN‐cr. Knockdown of y + LAT2 lead to significant leucine uptake inhibition (40%) and cell growth inhibition (20%). CONCLUSIONS New CRPC cell line with increased expression of y + LAT2 as a leucine transporter was established in vitro. Anti‐leucine transporter therapy could be an important option against prostate cancer. Prostate 77:222–233, 2017 . © 2016 Wiley Periodicals, Inc." @default.
• W2529944834 created "2016-10-21" @default.
• W2529944834 creator A5000287499 @default.
• W2529944834 creator A5034519956 @default.
• W2529944834 creator A5045237664 @default.
• W2529944834 creator A5068073788 @default.
• W2529944834 creator A5072727806 @default.
• W2529944834 creator A5086678014 @default.
• W2529944834 date "2016-10-03" @default.
• W2529944834 modified "2023-10-16" @default.
• W2529944834 title "Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters" @default.
• W2529944834 cites W1525354012 @default.
• W2529944834 cites W1540095279 @default.
• W2529944834 cites W1956844386 @default.
• W2529944834 cites W1964503720 @default.
• W2529944834 cites W1965204257 @default.
• W2529944834 cites W1972442346 @default.
• W2529944834 cites W1977473046 @default.
• W2529944834 cites W1977918192 @default.
• W2529944834 cites W1989591061 @default.
• W2529944834 cites W1991054305 @default.
• W2529944834 cites W2003551015 @default.
• W2529944834 cites W2007026131 @default.
• W2529944834 cites W2014476883 @default.
• W2529944834 cites W2015947287 @default.
• W2529944834 cites W2020700628 @default.
• W2529944834 cites W2023253424 @default.
• W2529944834 cites W2051025382 @default.
• W2529944834 cites W2058596530 @default.
• W2529944834 cites W2070513189 @default.
• W2529944834 cites W2071257247 @default.
• W2529944834 cites W2101257555 @default.
• W2529944834 cites W2102117986 @default.
• W2529944834 cites W2113962581 @default.
• W2529944834 cites W2115689849 @default.
• W2529944834 cites W2123964155 @default.
• W2529944834 cites W2125789330 @default.
• W2529944834 cites W2134138119 @default.
• W2529944834 cites W2137330819 @default.
• W2529944834 cites W2153710117 @default.
• W2529944834 cites W2160427174 @default.
• W2529944834 cites W2164010840 @default.
• W2529944834 cites W2165734378 @default.
• W2529944834 cites W2168850532 @default.
• W2529944834 doi "https://doi.org/10.1002/pros.23263" @default.
• W2529944834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27696482" @default.
• W2529944834 hasPublicationYear "2016" @default.
• W2529944834 type Work @default.
• W2529944834 sameAs 2529944834 @default.
• W2529944834 citedByCount "26" @default.
• W2529944834 countsByYear W25299448342017 @default.
• W2529944834 countsByYear W25299448342018 @default.
• W2529944834 countsByYear W25299448342019 @default.
• W2529944834 countsByYear W25299448342020 @default.
• W2529944834 countsByYear W25299448342021 @default.
• W2529944834 countsByYear W25299448342022 @default.
• W2529944834 countsByYear W25299448342023 @default.
• W2529944834 crossrefType "journal-article" @default.
• W2529944834 hasAuthorship W2529944834A5000287499 @default.
• W2529944834 hasAuthorship W2529944834A5034519956 @default.
• W2529944834 hasAuthorship W2529944834A5045237664 @default.
• W2529944834 hasAuthorship W2529944834A5068073788 @default.
• W2529944834 hasAuthorship W2529944834A5072727806 @default.
• W2529944834 hasAuthorship W2529944834A5086678014 @default.
• W2529944834 hasConcept C104317684 @default.
• W2529944834 hasConcept C121608353 @default.
• W2529944834 hasConcept C126322002 @default.
• W2529944834 hasConcept C134018914 @default.
• W2529944834 hasConcept C149011108 @default.
• W2529944834 hasConcept C1491633281 @default.
• W2529944834 hasConcept C153911025 @default.
• W2529944834 hasConcept C2776438761 @default.
• W2529944834 hasConcept C2776580952 @default.
• W2529944834 hasConcept C2777911890 @default.
• W2529944834 hasConcept C2779723316 @default.
• W2529944834 hasConcept C2780192828 @default.
• W2529944834 hasConcept C2781313199 @default.
• W2529944834 hasConcept C502942594 @default.
• W2529944834 hasConcept C515207424 @default.
• W2529944834 hasConcept C53227056 @default.
• W2529944834 hasConcept C55493867 @default.
• W2529944834 hasConcept C61367390 @default.
• W2529944834 hasConcept C62112901 @default.
• W2529944834 hasConcept C71315377 @default.
• W2529944834 hasConcept C71924100 @default.
• W2529944834 hasConcept C86803240 @default.
• W2529944834 hasConceptScore W2529944834C104317684 @default.
• W2529944834 hasConceptScore W2529944834C121608353 @default.
• W2529944834 hasConceptScore W2529944834C126322002 @default.
• W2529944834 hasConceptScore W2529944834C134018914 @default.
• W2529944834 hasConceptScore W2529944834C149011108 @default.
• W2529944834 hasConceptScore W2529944834C1491633281 @default.
• W2529944834 hasConceptScore W2529944834C153911025 @default.
• W2529944834 hasConceptScore W2529944834C2776438761 @default.
• W2529944834 hasConceptScore W2529944834C2776580952 @default.
• W2529944834 hasConceptScore W2529944834C2777911890 @default.
• W2529944834 hasConceptScore W2529944834C2779723316 @default.
• W2529944834 hasConceptScore W2529944834C2780192828 @default.

• next